Development and optimization of gastroretentive mucoadhesive microspheres of gabapentin by Box–Behnken design
Source abstract
Abstract
CONTEXT: Gabapentin follows saturation kinetics for absorption because of carrier-mediated transport and narrow absorption window in stomach. There is need to develop a gastroretentive formulation to maximize the absorption without crossing the saturation threshold for absorption. OBJECTIVE: The aim was to develop a gastroretentive formulation of gabapentin to increase the fraction of drug absorbed in stomach. MATERIALS AND METHODS: Sodium alginate and sodium carboxymethylcellulose were used to formulate the microsphere by ionotropic gelation with calcium chloride. The formulation was optimized using a three-factor, three-level Box-Behnken design. RESULTS: The particle size varied from 559.50 to 801.10 μm, entrapment efficiency from 61.29 to 81.00% and in vitro release from 69.40 to 83.70%. The optimized formulation was found using point-prediction, and formulation OF-3 showed optimum results at 608.21 μm size, 79.65% entrapment efficiency and 82.72% drug release and 81% mucoadhesion up to 10 h. The drug release was controlled for more than 12 h. DISCUSSION: The particle size was most influenced by sodium alginate while entrapment efficiency and drug release depended upon both polymers. The release followed Higuchi model. CONCLUSION: Gastroretentive formulation was successfully optimized by a three-factor, three-level Box-Behnken design and found to be useful.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. Barry GE · Epilepsy Res · 1998 · 31 · 9110.1016/S0920-1211(98)00020-5 ↗
2. Barry GE · Epilepsy Res · 2000 · 40 · 12310.1016/S0920-1211(00)00117-0 ↗
3. Baumgratner SK · Int J Pharm · 2000 · 195 · 12510.1016/S0378-5173(99)00378-6 ↗
4. Bordonart PL · J Control Release · 2006 · 111 · 110.1016/j.jconrel.2005.10.031 ↗
5. 10.1080/00401706.1960.1048991210.1080/00401706.1960.10489912 ↗
6. Box GEP · 1987
7. Chowdary KPR · AAPS PharmSciTech · 2003 · 4 · 1
8. Chowdary KPR · Saudi Pharm J · 2003 · 11 · 97
9. Draper NR · 1996 · 13 · 343
10. Gavin PA · Eur J Pharm Biopharm · 2009 · 71 · 50510.1016/j.ejpb.2008.09.028 ↗
11. Gonza´lez-Rodrıguez ML · Int J Pharm · 2002 · 232 · 22510.1016/S0378-5173(01)00915-2 ↗
12. Hoffman A · Adv Drug Del Rev · 1998 · 33 · 18510.1016/S0169-409X(98)00027-1 ↗
13. Hoffman A · Crit Rev Ther Drug Carrier Syst · 1999 · 16 · 57110.1615/CritRevTherDrugCarrierSyst.v16.i6.20 ↗
14. Hwang SJ · Crit Rev Ther Drug Carrier Syst · 1998 · 15 · 243
15. Montgomery DC · 2005
16. Mudahar GS · J Food Sci · 1989 · 54 · 71410.1111/j.1365-2621.1989.tb04688.x ↗
17. Myers RH · J Quality Technol · 2004 · 36 · 5310.1080/00224065.2004.11980252 ↗
18. 10.1208/s12249-010-9380-510.1208/s12249-010-9380-5 ↗
19. 10.1016/S0378-5173(02)00130-810.1016/S0378-5173(02)00130-8 ↗
20. Pawar VK · Expert Opin Drug Deliv · 2012 · 9 · 55110.1517/17425247.2012.677431 ↗
21. 10.1208/s12249-008-9041-010.1208/s12249-008-9041-0 ↗
22. 10.1016/j.ijpharm.2011.03.04810.1016/j.ijpharm.2011.03.048 ↗
23. 10.1016/0378-5173(89)90229-910.1016/0378-5173(89)90229-9 ↗
24. 10.1016/S0939-6411(97)00154-910.1016/S0939-6411(97)00154-9 ↗
25. 10.1211/002235799177295210.1211/0022357991772952 ↗
26. Sultana S · J Microencaps · 2009 · 29 · 38510.1080/02652040802376429 ↗
27. Sultana Y · J Dispersion Sci Technol · 2011 · 32 · 42410.1080/01932691003662456 ↗
28. 10.1016/j.ijpharm.2009.05.02510.1016/j.ijpharm.2009.05.025 ↗
29. Tripathi KD · 200810.5005/jp/books/10282 ↗